(PSYCHIATRIC TIMES) - Death as a result of cardiovascular (CV) complications represents the leading natural cause of excess mortality in patients with schizophrenia.1 While lifestyle variables such as high rates of smoking, poor dietary habits, and inactivity contribute to CV disease, research has also focused on a cluster of abnormalities that define metabolic syndrome (Table 1). Although considerable debate exists about whether a diagnosis of metabolic syndrome confers added CV risk compared with that attributable to the individual criteria, there is little doubt that the syndrome captures a group of individuals at risk for both CV disease and type 2 diabetes mellitus.2
The clinical usefulness of the metabolic syndrome concept is its ability to focus attention on a cluster of abnormalities that in isolation may not attract much clinical interest. Underlying the development of metabolic syndrome (also referred to as syndrome X or the dysmetabolic syndrome) is the finding that compensatory hyperinsulinemia, in certain abdominally obese persons, is associated with dyslipidemia, hypertension, and inflammatory markers.3 Those features distinguish patients with metabolic syndrome from overweight or obese individuals in whom hyperinsulinemia develops in the presence of decreased peripheral insulin sensitivity but without the other dysmetabolic components.
Increased diabetes mellitus prevalence has been noted in patients with schizophrenia in many countries,4 but the greater public health concern is the prevention of diabetes and preservation of b-cell function in patients who are prediabetic.5 For that reason, recent studies of patients with schizophrenia have increasingly focused on the prevalence of prediabetic states such as the metabolic syndrome. Issues in the literature revolve around the prevalence of the syndrome as a whole and that of the individual criteria, how these prevalence data compare with those in matched individuals from the general population, and the role of antipsychotic medications.
The purpose of this article is to review some of the newer findings that probe the link between metabolic syndrome and schizophrenia and to investigate whether compelling data exist to demonstrate medication-independent risk for metabolic disease in patients with schizophrenia. Recent consensus recommendations for monitoring and preventing metabolic dysfunction will be discussed, along with studies outlining comparative therapeutic options for those who meet metabolic syndrome criteria.
Prevalence data, disease, and medication effects
The diagnostic criteria used in many studies are based on those elaborated by the National Cholesterol Education Program (NCEP) in 20016 and subsequently updated by lowering the fasting glucose threshold to 100 mg/dL to match that established by the American Diabetes Association (ADA) for prediabetes7 (Table 1). Although abdominal obesity is considered a core feature of the syndrome, the NCEP definition allowed the diagnosis to be established by meeting any 3 of the 5 criteria, prompting the International Diabetes Federation (IDF) to create a newer definition that mandates abdominal obesity as a necessary criterion, combined with any 2 of the 4 remaining components.
Regardless of the definition, the past 2 years have seen the publication of multiple articles on the prevalence of metabolic syndrome, predominantly using North American or Western European samples, including several large studies that compared prevalences in patients with schizophrenia with those in matched comparison controls from the general population (Table 2). 8-10 Among the recent studies, 2 recruited patients with schizophrenia or schizoaffective disorder on the basis of obesity11,12 and have limited generalizability.
The first large published estimate is from a study of 240 Canadian patients with schizophrenia or schizoaffective disorder (65% male, mean age 43.3 years). The investigators found a prevalence of 42.6% for men and 48.5% for women, using the NCEP criteria8; these rates are 2-fold greater than comparable published estimates in the United States. In their study using a cohort born in 1966 in northern Finland, Saari and colleagues10 found a 4-fold increased risk for NCEP-defined metabolic syndrome in the 31 patients with schizophrenia compared with their 5500 demographically identical peers. The largest non-US data set is an analysis of 430 Belgian patients with schizophrenia that, using NCEP criteria, showed a prevalence of 28.4% for metabolic syndrome (32.3% with the updated NCEP definition and 36.0% using the IDF definition). Again, this prevalence for metabolic syndrome was at least twice as high as that of an age-adjusted community sample in Belgium.13
The most comprehensive and largest comparative analysis of metabolic syndrome prevalence emerged from the baseline sample in the National Institute of Mental Health–funded Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial.9 The data-dense findings from multiple analyses of metabolic syndrome and prevalence criteria on the basis of age, sex, and race/ethnicity were compared with a demographically matched sample from the Third National Health and Nutrition Examination Survey (NHANES III).
There were several important findings of CATIE worth highlighting, including the fact that increased metabolic syndrome prevalence (compared with NHANES III) was seen across nearly all individual metabolic syndrome criteria for men and women (Table 3). The discrepancy in prevalence was found in patients with schizophrenia as young as those aged 20 through 30 and was always greatest for women. A sex difference in metabolic syndrome prevalence was found in the general population (approximately 25% greater in women),14 but this difference was magnified to 42% within the schizophrenia population. Adding further clinical concern were the low rates of treatment for metabolic syndrome components evaluated as part of CATIE.15
For full article, please visit: